Loading clinical trials...
Loading clinical trials...
Canadian Advanced Parkinson DUODOPA-Treated Patients Observational Study Evaluating Long-Term Health Outcomes in Centers of Excellence (CADENCE)
This is an open-label, postmarketing, observational study to document health outcomes, in Canadian patients with advanced Parkinson's disease and long-term treatment with Duodopa (levodopa/carbidopa intestinal gel).
Age
18 - 99 years
Sex
ALL
Healthy Volunteers
No
University of Calgary /ID# 151948
Calgary, Alberta, Canada
Zeidler Ledcor Centre /ID# 135979
Edmonton, Alberta, Canada
St. Boniface Clinic, CA /ID# 162092
Winnipeg, Manitoba, Canada
Hamilton Health Sciences /ID# 148808
Hamilton, Ontario, Canada
Kingston General Hospital /ID# 144942
Kingston, Ontario, Canada
London Health Sciences Centre /ID# 138434
London, Ontario, Canada
The Ottawa Hospital /ID# 135981
Ottawa, Ontario, Canada
Toronto Western Hospital /ID# 135980
Toronto, Ontario, Canada
CHUM - Notre-Dame Hospital /ID# 135977
Montreal, Quebec, Canada
McGill Univ HC /ID# 138334
Montreal, Quebec, Canada
Start Date
October 19, 2015
Primary Completion Date
February 26, 2020
Completion Date
February 26, 2020
Last Updated
June 25, 2021
88
ACTUAL participants
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07414290